Alzamend director sells final 2,000 direct shares
Alzamend Neuro, Inc. (ALZN) director Milton C. Ault III reported selling 2,000 shares of common stock in open-market transactions on August 26, 2026 at a volume weighted average price of $1.5581 per share, reducing his directly held shares to 0.
Rhea-AI Filing Summary
Alzamend Neuro, Inc. (ALZN) director Milton C. Ault III reported selling 2,000 shares of common stock in open-market transactions on August 26, 2026 at a volume weighted average price of $1.5581 per share, reducing his directly held shares to 0. He continues to report indirect ownership of Alzamend Neuro common stock, including shares held through Ault Lending, LLC, Ault Life Sciences, Inc., and Ault Life Sciences Fund, LLC. Ault calculated a short-swing profit on matchable transactions that he intends to disgorge to Alzamend Neuro under Section 16(b) of the Exchange Act.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 2,000 shares
Net Sell
4 txns
Insider
AULT MILTON C III
Role
Director
Sold
2,000 shs ($3K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 2,000 | $1.5581 | $3K |
| holding | Common Stock F3 | -- | -- | -- |
| holding | Common Stock F4 | -- | -- | -- |
| holding | Common Stock F5 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 0 shares (Direct);
Common Stock — 116,648 shares (Indirect, By Ault Lending, LLC);
Common Stock — 11,068 shares (Indirect, By Ault Life Sciences, Inc.);
Common Stock — 61 shares (Indirect, By Ault Life Sciences Fund, LLC)
Footnotes (5)
- F1. The sale of these shares is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer.
- F2. The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sale price of $1.5581. The range of sale prices on the transaction date was $1.55 to $1.5619 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
- F3. Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Ault Capital Group, Inc. ("ACG"). ACG is a wholly-owned subsidiary of Hyperscale Data, Inc. ("HSD"). Mr. Ault, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending.
- F4. Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc.
- F5. Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC.
Key Figures
Shares sold: 2,000 shares of Common Stock
Volume weighted average sale price: $1.5581 per share
Direct holdings after transaction: 0 shares
+3 more
6 metrics
Shares sold
2,000 shares of Common Stock
Sale on August 26, 2026
Volume weighted average sale price
$1.5581 per share
Open-market sales on August 26, 2026; price range $1.55–$1.5619
Direct holdings after transaction
0 shares
Common Stock directly held by reporting person following sale
Indirect holdings via Ault Lending, LLC
116,648 shares
Common Stock held of record by Ault Lending, LLC
Indirect holdings via Ault Life Sciences, Inc.
11,068 shares
Common Stock held of record by Ault Life Sciences, Inc.
Indirect holdings via Ault Life Sciences Fund, LLC
61 shares
Common Stock held of record by Ault Life Sciences Fund, LLC
Key Terms
Section 16(b), short-swing profit, volume weighted average sale price, disgorge, +1 more
5 terms
Section 16(b) regulatory
"matchable transaction subject to Section 16(b) of the Securities Exchange Act"
A federal rule that requires company insiders—like officers, directors and large shareholders—to return any profits made from buying and selling the company’s stock within a six-month window. It matters to investors because it discourages short-term trades that could exploit non-public information and helps protect outside shareholders by creating a simple, enforceable way to recover unfair gains, much like a rule stopping someone from flipping a limited-edition item for quick profit after getting early access.
short-swing profit regulatory
"calculated a short-swing profit in connection with such matchable transactions"
Short-swing profit is any gain an insider makes from buying and selling (or selling and buying) the same company's stock or options within a six-month window; regulators treat those quick trades as presumptively improper and typically require the profits to be returned. Think of it like flipping a concert ticket for a quick markup — the law prevents insiders with privileged access from keeping those fast gains, which protects ordinary investors and promotes fair markets.
volume weighted average sale price financial
"with a volume weighted average sale price of $1.5581"
disgorge regulatory
"which the reporting person intends to disgorge to the Issuer"
indirect ownership financial
"securities held of record by Ault Lending, LLC"
FAQ
What insider transaction did ALZN director Milton C. Ault III report?
He reported a sale of 2,000 shares of Alzamend Neuro common stock on August 26, 2026 in open-market transactions at a volume weighted average price of $1.5581 per share, leaving him with no directly held shares reported after the transaction.
Were the ALZN insider sales made under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is not marked as true, and there is no footnote stating that these transactions were made pursuant to a Rule 10b5-1 trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
